Alphamab Oncology
HKEX:9966.HK
3.38 (HKD) • At close January 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2024 Q2 | 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | 2018 Q4 | 2018 Q2 | 2017 Q4 | 2017 Q2 | 2016 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 173.561 | 82.309 | 136.465 | 113.276 | 53.569 | 146.021 | 0 | 0 | 0 | 2.434 | 2.558 | -1.081 | 0.346 | 0 | 0 | 0 |
| Cost of Revenue
| 30.807 | 22.072 | 33.165 | 29.387 | 14.82 | 3.028 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 142.754 | 60.237 | 103.3 | 83.889 | 38.749 | 142.993 | 0 | 0 | 0 | 2.434 | 2.558 | -1.081 | 0.346 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.823 | 0.732 | 0.757 | 0.741 | 0.723 | 0.979 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 194.531 | 212.843 | 194.681 | 251.839 | 216.399 | 249.414 | 231.947 | 197.517 | 133.724 | 110.902 | 55.752 | 39.031 | 26.577 | 16.402 | 26.611 | 13.305 |
| General & Administrative Expenses
| 34.635 | 46.094 | 33.244 | 42.674 | 44.097 | 39.12 | 38.131 | 37.629 | 40.579 | 93.075 | 24.661 | 16.617 | 9.24 | 3.329 | 3.316 | 1.658 |
| Selling & Marketing Expenses
| 0.086 | 0.038 | 0.187 | 0.004 | 0.165 | -0.036 | 0.335 | -0.02 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 34.721 | 46.132 | 33.431 | 42.678 | 44.262 | 39.084 | 38.466 | 37.609 | 40.599 | 93.075 | 24.661 | 16.617 | 9.24 | 3.329 | 3.316 | 1.658 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -287.521 | 0 | -56.815 | -46.453 | -23.226 |
| Operating Expenses
| 229.252 | 258.975 | 173.925 | 276.956 | 191.064 | 295.362 | 274.673 | 349.142 | 131.458 | 794.008 | 80.413 | 100.542 | 35.817 | -37.084 | -16.527 | -8.263 |
| Operating Income
| -86.498 | -198.738 | -124.625 | -210.624 | -221.747 | -145.541 | -270.078 | -235.146 | -174.303 | -201.543 | -77.855 | -56.729 | -35.471 | -37.084 | -16.527 | -8.263 |
| Operating Income Ratio
| -0.498 | -2.415 | -0.913 | -1.859 | -4.139 | -0.997 | 0 | 0 | 0 | -82.803 | -30.436 | 52.478 | -102.517 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 41.602 | 28.007 | 84.95 | 32.211 | 74.438 | 0.488 | 2.714 | -89.52 | 71.223 | -572.412 | 19.07 | -45.862 | -64.571 | -13.574 | -15.887 | -7.943 |
| Income Before Tax
| -44.896 | -170.731 | -39.862 | -178.413 | -147.309 | -145.053 | -267.364 | -324.666 | -103.1 | -773.955 | -58.785 | -102.591 | -100.042 | -50.658 | -32.413 | -16.207 |
| Income Before Tax Ratio
| -0.259 | -2.074 | -0.292 | -1.575 | -2.75 | -0.993 | 0 | 0 | 0 | -317.977 | -22.981 | 94.904 | -289.139 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0.038 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.902 | 0 | 0.377 | 0.004 | 0.002 |
| Net Income
| -44.896 | -170.731 | -39.862 | -178.413 | -147.309 | -145.053 | -267.364 | -324.666 | -103.1 | -773.955 | -58.785 | -97.892 | -51.951 | -51.035 | -32.417 | -16.209 |
| Net Income Ratio
| -0.259 | -2.074 | -0.292 | -1.575 | -2.75 | -0.993 | 0 | 0 | 0 | -317.977 | -22.981 | 90.557 | -150.147 | 0 | 0 | 0 |
| EPS
| -0.05 | -0.18 | -0.042 | -0.19 | -0.16 | -0.15 | -0.29 | -0.35 | -0.11 | -1.39 | -0.12 | -0.21 | -0.21 | -0.057 | -0.036 | -0.018 |
| EPS Diluted
| -0.047 | -0.18 | -0.042 | -0.19 | -0.16 | -0.15 | -0.29 | -0.35 | -0.11 | -1.39 | -0.088 | -0.21 | -0.21 | -0.057 | -0.036 | -0.018 |
| EBITDA
| -55.627 | -168.52 | -99.021 | -186.006 | -205.823 | -130.605 | -256.493 | -224.713 | -165.756 | -200.059 | -77.511 | -56.52 | -35.414 | -35.444 | -16.27 | -8.135 |
| EBITDA Ratio
| -0.321 | -2.047 | -0.726 | -1.642 | -3.842 | -0.894 | 0 | 0 | 0 | -82.194 | -30.301 | 52.285 | -102.353 | 0 | 0 | 0 |